Literature DB >> 31720719

[Supportive therapy and management of side effects in dermato-oncology].

Laura von Dücker1, Svea Hüning2, Katharina Kähler3, Patrick Terheyden4, Do Ro Thée Nashan2.   

Abstract

In the context of supportive therapy, possible complaints which may be caused by the cancer itself, by the antitumoral therapy or by psychosocial concerns are considered. Due to the introduction of new anticancer drugs in dermato-oncology, clinicians are confronted with a novel spectrum of adverse events. There are a number of inflammatory, immune-mediated side effects caused by immunotherapies, which can affect virtually any organ. Targeted therapies also have specific side effects. Basically, the management of adverse events depends on their severity. Besides treatment breaks and dosage modifications, immunotherapy-related adverse events are treated with systemic immunosuppressants. Supportive symptomatic therapy is offered. The additional consideration of psychosocial problems can improve quality of life of cancer patients.

Entities:  

Keywords:  Dosage modifications; Immunotherapy; Quality of life; Targeted therapy; Treatment breaks

Mesh:

Substances:

Year:  2019        PMID: 31720719     DOI: 10.1007/s00105-019-04496-z

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  66 in total

Review 1.  Avelumab: A Review in Metastatic Merkel Cell Carcinoma.

Authors:  Matt Shirley
Journal:  Target Oncol       Date:  2018-06       Impact factor: 4.493

Review 2.  [Psycho-oncological aspects of malignant melanoma. A systematic review from 1990-2008].

Authors:  M E Beutel; M Blettner; S Fischbeck; C Loquay; A Werner; H Marian
Journal:  Hautarzt       Date:  2009-09       Impact factor: 0.751

3.  Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids.

Authors:  Mirjana Ziemer; Eleni Koukoulioti; Susanne Beyer; Jan C Simon; Thomas Berg
Journal:  J Hepatol       Date:  2016-11-28       Impact factor: 25.083

Review 4.  Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.

Authors:  Alexander Faje
Journal:  Pituitary       Date:  2016-02       Impact factor: 4.107

5.  Guarana (Paullinia cupana) improves fatigue in breast cancer patients undergoing systemic chemotherapy.

Authors:  Maira Paschoin de Oliveira Campos; Rachel Riechelmann; Lourdes Conceição Martins; Benjamin J Hassan; Fernanda Branco Assunção Casa; Auro Del Giglio
Journal:  J Altern Complement Med       Date:  2011-05-25       Impact factor: 2.579

6.  Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.

Authors:  Paolo A Ascierto; Grant A McArthur; Brigitte Dréno; Victoria Atkinson; Gabrielle Liszkay; Anna Maria Di Giacomo; Mario Mandalà; Lev Demidov; Daniil Stroyakovskiy; Luc Thomas; Luis de la Cruz-Merino; Caroline Dutriaux; Claus Garbe; Yibing Yan; Matthew Wongchenko; Ilsung Chang; Jessie J Hsu; Daniel O Koralek; Isabelle Rooney; Antoni Ribas; James Larkin
Journal:  Lancet Oncol       Date:  2016-07-30       Impact factor: 41.316

Review 7.  Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.

Authors:  Adil Daud; Katy Tsai
Journal:  Oncologist       Date:  2017-05-18

Review 8.  The Impact of Exercise on Cancer Mortality, Recurrence, and Treatment-Related Adverse Effects.

Authors:  Prue Cormie; Eva M Zopf; Xiaochen Zhang; Kathryn H Schmitz
Journal:  Epidemiol Rev       Date:  2017-01-01       Impact factor: 6.222

9.  Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer.

Authors:  Sriram Yennurajalingam; Susan Frisbee-Hume; J Lynn Palmer; Marvin O Delgado-Guay; Janet Bull; Alexandria T Phan; Nizar M Tannir; Jennifer Keating Litton; Akhila Reddy; David Hui; Shalini Dalal; Lisa Massie; Suresh K Reddy; Eduardo Bruera
Journal:  J Clin Oncol       Date:  2013-07-29       Impact factor: 44.544

Review 10.  Merkel Cell Carcinoma: Therapeutic Update and Emerging Therapies.

Authors:  Alessia Villani; Gabriella Fabbrocini; Claudia Costa; Maria Carmela Annunziata; Massimiliano Scalvenzi
Journal:  Dermatol Ther (Heidelb)       Date:  2019-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.